INTRODUCTION: The patterns of failure and mechanisms of sarcoma-specific death are poorly characterized among the minority of patients with low-grade soft tissue sarcoma (STS) who succumb to disease. METHODS: Between 1982 and 2006, 2,041 patients aged >or=16 years with low-grade STS of all sites were treated with curative intent and prospectively followed at a single institution. RESULTS: Among this cohort, 181 (9%) died from disease (DOD). Overall, 105 patients (58%) died from locally recurrent disease (DOLR), and 59 (32%) died from distant disease (DODR). In 17 patients (9%), the mechanism of sarcoma-related death could not be verified. DOD occurred at a median of 62 months, while median disease-specific survival for the entire cohort was not reached. Median follow-up was 66 months (range 2-431 months). On multivariate analysis, DOD was associated with site, size, and less than R0 resection. For DOLR, site, size, positive margins, liposarcoma histology, and local recurrence (by definition) were significant factors. For DODR, site, histology, and positive margins were not significant factors, while size and local recurrence were. Of DOLR, 80% were retroperitoneal, 68% were liposarcoma, and only 2% were extremity. Conversely, of DODR, extremity (47%) and trunk (18%) were the most common sites, but histology was more variable [liposarcoma 35%, malignant fibrous histiocytoma (MFH) 20%, fibrosarcoma 12%, extraskeletal myxoid chondrosarcoma 10%]. High-grade recurrence rates were comparable between DOLR (27%) and DODR (25%). CONCLUSION: Among patients with low-grade STS, DOD occurs in approximately 9% of patients. Nonextremity site, larger size, and less than R0 resection are the most important risk factors for DOD, and distinct patterns of recurrence and death are predicted by primary tumor site.
INTRODUCTION: The patterns of failure and mechanisms of sarcoma-specific death are poorly characterized among the minority of patients with low-grade soft tissue sarcoma (STS) who succumb to disease. METHODS: Between 1982 and 2006, 2,041 patients aged >or=16 years with low-grade STS of all sites were treated with curative intent and prospectively followed at a single institution. RESULTS: Among this cohort, 181 (9%) died from disease (DOD). Overall, 105 patients (58%) died from locally recurrent disease (DOLR), and 59 (32%) died from distant disease (DODR). In 17 patients (9%), the mechanism of sarcoma-related death could not be verified. DOD occurred at a median of 62 months, while median disease-specific survival for the entire cohort was not reached. Median follow-up was 66 months (range 2-431 months). On multivariate analysis, DOD was associated with site, size, and less than R0 resection. For DOLR, site, size, positive margins, liposarcoma histology, and local recurrence (by definition) were significant factors. For DODR, site, histology, and positive margins were not significant factors, while size and local recurrence were. Of DOLR, 80% were retroperitoneal, 68% were liposarcoma, and only 2% were extremity. Conversely, of DODR, extremity (47%) and trunk (18%) were the most common sites, but histology was more variable [liposarcoma 35%, malignant fibrous histiocytoma (MFH) 20%, fibrosarcoma 12%, extraskeletal myxoid chondrosarcoma 10%]. High-grade recurrence rates were comparable between DOLR (27%) and DODR (25%). CONCLUSION: Among patients with low-grade STS, DOD occurs in approximately 9% of patients. Nonextremity site, larger size, and less than R0 resection are the most important risk factors for DOD, and distinct patterns of recurrence and death are predicted by primary tumor site.
Authors: J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: J J Gaynor; C C Tan; E S Casper; C F Collin; C Friedrich; M Shiu; S I Hajdu; M F Brennan Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: M Trojani; G Contesso; J M Coindre; J Rouesse; N B Bui; A de Mascarel; J F Goussot; M David; F Bonichon; C Lagarde Journal: Int J Cancer Date: 1984-01-15 Impact factor: 7.396
Authors: Stefan Welter; Florian Grabellus; Sebastian Bauer; Kurt Werner Schmid; Georgios Stamatis; Martin Tötsch Journal: Virchows Arch Date: 2011-07-06 Impact factor: 4.064
Authors: Dhruvil Shah; Dariusz Borys; Steve R Martinez; Chin-Shang Li; Robert M Tamurian; Richard J Bold; Arta Monjazeb; Robert J Canter Journal: Anticancer Res Date: 2012-09 Impact factor: 2.480
Authors: Richard J Straker; Yun Song; Adrienne B Shannon; Clayton T Marcinak; John T Miura; Douglas L Fraker; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2021-02-16 Impact factor: 5.344
Authors: Philip Wong; Peter Houghton; David G Kirsch; Steven E Finkelstein; Arta M Monjazeb; Meng Xu-Welliver; Adam P Dicker; Mansoor Ahmed; Bhadrasain Vikram; Beverly A Teicher; C Norman Coleman; Mitchell Machtay; Walter J Curran; Dian Wang Journal: J Natl Cancer Inst Date: 2014-10-18 Impact factor: 13.506
Authors: Robert J Canter; Steve R Martinez; Robert M Tamurian; Maaya Wilton; Chin-Shang Li; Janice Ryu; Walter Mak; Wayne L Monsky; Dariusz Borys Journal: Ann Surg Oncol Date: 2010-06-17 Impact factor: 5.344
Authors: Wayne L Monsky; Bedro Jin; Chris Molloy; Robert J Canter; Chin Shang Li; Tzu C Lin; Daniel Borys; Walter Mack; Isaac Kim; Michael H Buonocore; Abhijit J Chaudhari Journal: Anticancer Res Date: 2012-11 Impact factor: 2.480